Armitage JO - Search Results

1

High-dose chemotherapy and autologous transplant with peripheral-blood stem cells.

Vose JM, Armitage JO, Kessinger A. Vose JM, et al. Among authors: armitage jo. Oncology (Williston Park). 1993 Aug;7(8):23-9; discussion 29-30, 33-4. Oncology (Williston Park). 1993. PMID: 8104456

2

Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.

Vose JM, Sharp G, Chan WC, Nichols C, Loh K, Inwards D, Rifkin R, Bierman PJ, Lynch JC, Weisenburger DD, Kessinger A, Armitage JO. Vose JM, et al. Among authors: armitage jo. J Clin Oncol. 2002 May 1;20(9):2344-52. doi: 10.1200/JCO.2002.09.138. J Clin Oncol. 2002. PMID: 11981006 Clinical Trial.

3

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.

Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC, Armitage JO. Vose JM, et al. Among authors: armitage jo. J Clin Oncol. 2005 Jan 20;23(3):461-7. doi: 10.1200/JCO.2005.05.117. Epub 2004 Nov 8. J Clin Oncol. 2005. PMID: 15534357 Clinical Trial.

4

Follicular lymphoma: expanding therapeutic options.

Ganti AK, Bociek RG, Bierman PJ, Enke CA, Vose JM, Armitage JO. Ganti AK, et al. Among authors: armitage jo. Oncology (Williston Park). 2005 Feb;19(2):213-28; discussion 228, 233-6, 239. Oncology (Williston Park). 2005. PMID: 15770890 Free article. Review.

5

Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.

Pavletic SZ, Smith LM, Bishop MR, Lynch JC, Tarantolo SR, Vose JM, Bierman PJ, Hadi A, Armitage JO, Kessinger A. Pavletic SZ, et al. Among authors: armitage jo. Am J Hematol. 2005 Apr;78(4):265-74. doi: 10.1002/ajh.20275. Am J Hematol. 2005. PMID: 15795914 Free article.

6

Lymphoma 2006: classification and treatment.

Armitage JO, Bierman PJ, Bociek RG, Vose JM. Armitage JO, et al. Oncology (Williston Park). 2006 Mar;20(3):231-9; discussion 242, 244, 249. Oncology (Williston Park). 2006. PMID: 16629256 Free article. Review.

7

Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation.

Vose JM, Bierman PJ, Loberiza FR Jr, Bociek RG, Matso D, Armitage JO. Vose JM, et al. Among authors: armitage jo. Leuk Lymphoma. 2007 Apr;48(4):683-90. doi: 10.1080/10428190601158639. Leuk Lymphoma. 2007. PMID: 17454625 Clinical Trial.

8

Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.

Vose JM, Bierman PJ, Loberiza FR, Enke C, Hankins J, Bociek RG, Chan WC, Weisenburger DD, Armitage JO. Vose JM, et al. Among authors: armitage jo. Biol Blood Marrow Transplant. 2013 Jan;19(1):123-8. doi: 10.1016/j.bbmt.2012.08.013. Epub 2012 Aug 29. Biol Blood Marrow Transplant. 2013. PMID: 22940055 Free article. Clinical Trial.

9

Cryopreservation and infusion of autologous peripheral blood stem cells.

Kessinger A, Schmit-Pokorny K, Smith D, Armitage J. Kessinger A, et al. Bone Marrow Transplant. 1990 Jan;5 Suppl 1:25-7. Bone Marrow Transplant. 1990. PMID: 1969303 No abstract available.

10

Clinical outcome of peripheral blood stem cell support.

Kessinger A, Armitage J, Bierman P, Bishop M, Joshi S, Reed E, Sharp G, Talmadge J, Vose J. Kessinger A, et al. Med Oncol. 1994;11(2):43-6. doi: 10.1007/BF02988829. Med Oncol. 1994. PMID: 7850263 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

591 results

Search Page

Filters